Suppr超能文献

[新辅助同步放化疗用于晚期直肠癌的初步结果]

[First results of neoadjuvant simultaneious radiochemotherapy in advanced rectal carcinoma].

作者信息

Küchenmeister U, Kirchner R, Mellert J, Klautke G, Mücke R, Hopt U T, Fietkau R

机构信息

Klinik und Poliklinik für Strahlentherapie, Universität Rostock.

出版信息

Strahlenther Onkol. 2000 Dec;176(12):560-6. doi: 10.1007/pl00002325.

Abstract

PURPOSE

In locally advanced rectal cancer tumor-negative margins often cannot be obtained by surgery alone. Nevertheless only patients with complete tumor resection can be cured. Due to the poor prognosis of patients with R1/R2 resection the "Deutsche Krebsgesellschaft" recommends concurrent preoperative radiochemotherapy for patients with locally advanced rectal cancer.

PATIENTS AND METHODS

Between May 1997 and November 1999 22 patients were treated with preoperative radiochemotherapy. A total dose of 45 Gy with a small-volume boost of 5.4 Gy was delivered in conventional fractionation (single dose 1.8 Gy). On days 1 to 5 and 29 to 33 patients received concurrently 5-fluorouracil (5-FU) as continuous infusion of 1,000 mg/m2. If there was any sign of cardiac toxicity chemotherapy was changed to 5-FU/folinic acid or ralitrexed.

RESULTS

Surgery following radiochemotherapy was performed in 19/22 patients. Resections with negative margins were achieved in 16/19 (84%) patients. Sphincter-conserving surgery was possible in 9/19 (47%) patients. A downstaging of at least 1 T category was found in 12/19 (63%) patients. With a median follow-up of 16 months no locoregional recurrences occurred in patients who underwent surgery. Two-year disease-free survival of resected patients is 62%, 2-year overall survival is 89%, of the whole population 76%.

CONCLUSION

Preoperative radiochemotherapy followed by surgery is able to achieve clear resection margins in more than 70% of patients with locally advanced rectal cancer and may improve the rate of sphincter-conserving surgery.

摘要

目的

在局部晚期直肠癌中,仅通过手术往往无法获得肿瘤阴性切缘。然而,只有肿瘤完全切除的患者才能治愈。鉴于R1/R2切除患者的预后较差,“德国癌症协会”建议对局部晚期直肠癌患者进行术前同步放化疗。

患者与方法

1997年5月至1999年11月期间,22例患者接受了术前放化疗。采用常规分割方式(单次剂量1.8 Gy)给予总剂量45 Gy,并对小体积区域追加5.4 Gy的放疗剂量。在第1至5天和第29至33天,患者同时接受5-氟尿嘧啶(5-FU)持续静脉输注,剂量为1000 mg/m²。若出现任何心脏毒性迹象,则将化疗方案改为5-FU/亚叶酸或雷替曲塞。

结果

22例患者中有19例在放化疗后接受了手术。19例患者中有16例(84%)实现了切缘阴性切除。19例患者中有9例(47%)可行保肛手术。19例患者中有12例(63%)至少实现了1个T分期的降期。中位随访16个月,接受手术的患者未发生局部区域复发。切除患者的2年无病生存率为62%,2年总生存率为89%,总体人群的2年总生存率为76%。

结论

术前放化疗后行手术能够使超过70%的局部晚期直肠癌患者获得切缘阴性切除,且可能提高保肛手术率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验